Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium

Gerald L. Murray, Catriona S. Bradshaw, Melanie Bissessor, Jennifer A Danielewski, Suzanne M. Garland, Jørgen S. Jensen, Christopher K. Fairley, Sepehr N. Tabrizi

Research output: Contribution to journalArticleResearchpeer-review

118 Citations (Scopus)


Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failure. Macrolide/fluoroquinolone-resistance mutations were in 8.6% of specimens, for which recommended therapies would be ineffective.

Original languageEnglish
Pages (from-to)809-812
Number of pages4
JournalEmerging Infectious Diseases
Issue number5
Publication statusPublished - 1 May 2017

Cite this